Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 18, 2008
Boston Scientific Corporation today announced enrollment of the first patient...
-
Dec 15, 2008First low-profile, pre-mounted stent approved specifically for use in renal arteries
Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the Express® SD Renal Monorail®...
-
Nov 24, 2008
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held December 2 -...
-
Nov 10, 2008New design provides more options for treating patients with complex lesions
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its...
-
Oct 29, 2008
Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...
-
Oct 27, 2008Confirms clinical value and cost-effectiveness of spinal cord stimulation
Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...
-
Oct 23, 2008Leading carotid stent in Europe and other international markets now available in the United States
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Carotid WALLSTENT®...
-
Oct 21, 2008
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2008, as well as guidance for...
-
Oct 15, 2008Landmark trial provides new insight for physicians
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI...
-
Oct 15, 2008
Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the Intercontinental and European launch...
-
Oct 14, 2008New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients
Boston Scientific Corporation (NYSE: BSX) today announced 12-month left main and three-vessel disease subset data from its landmark...
-
Oct 14, 2008Company moves up Q3 earnings release date
Boston Scientific Corporation (NYSE: BSX) today provided the following comments reinforcing the strength of its balance sheet: The volatility of...
-
Oct 14, 2008TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts
Boston Scientific Corporation (NYSE: BSX) today announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based...
-
Oct 13, 2008Joint efforts will focus on intravascular ultrasound (IVUS)
GE Healthcare (NYSE: GE) and intravascular ultrasound (IVUS) market leader Boston Scientific Corporation (NYSE: BSX) today...
-
Oct 13, 2008
Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...
-
Oct 12, 2008
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1...
-
Oct 12, 2008New coronary stent features thin struts designed for more uniform drug delivery
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of...
-
Oct 10, 2008
Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its...
-
Oct 10, 2008
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular...
-
Oct 9, 2008
Yesterday saw heavy trading in Boston Scientific's (NYSE: BSX) stock, with approximately 38 million shares traded. This trading included involuntary...
-
Oct 8, 2008
Boston Scientific (NYSE: BSX) announced today it expects to record the following adjustments to its third quarter results, which it plans to report...
-
Oct 8, 2008PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the PERSEUS trial, designed to evaluate the Company's...
-
Oct 1, 2008
Boston Scientific Corporation (NYSE: BSX) announced today that the United States District Court in Delaware has entered judgment against the Company...
-
Sep 25, 2008Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market...
-
Sep 19, 2008
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the UBS Global Life Sciences Conference, which is being held September 22...